Brought to you by

Seres Therapeutics nets $143mm via IPO
02 Jul 2015
Executive Summary
Seres Therapeutics Inc. (formerly Seres Health; studies the microbiome) netted $143mm through its initial public offering of 8.5mm common shares (including the overallotment) at $18 each. The company originally thought it would sell 6.25mm shares between $15 and $17.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com